Optimizing parameters in clinical trials with a randomized start or withdrawal design
暂无分享,去创建一个
Feng Gao | John C. Morris | Chengjie Xiong | Jingqin Luo | J. Morris | F. Gao | C. Xiong | Jingqin R Luo | J. Morris | J. Morris | C. Xiong
[1] J. Bunch,et al. Differential Vulnerability , 2016 .
[2] F. Mantelli,et al. Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease , 2013, British Journal of Ophthalmology.
[3] M. Sano,et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease , 2011, Neurology.
[4] P. Aisen,et al. A phase II trial of huperzine A in mild to moderate Alzheimer disease , 2011, Neurology.
[5] B. Brunekreef,et al. Methodological Issues and Statistical Analysis in Land Use Regression Modeling , 2011 .
[6] Mark A Mintun,et al. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. , 2009, Archives of neurology.
[7] J. Morris,et al. Longitudinal study of the transition from healthy aging to Alzheimer disease. , 2009, Archives of neurology.
[8] C. Xiong,et al. Commentary on “A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.” Prevention trials in persons at risk for dominantly inherited Alzheimer's disease: Opportunities and challenges , 2009, Alzheimer's & Dementia.
[9] Shein-Chung Chow,et al. Adaptive design methods in clinical trials – a review , 2008, Orphanet journal of rare diseases.
[10] J. Cummings,et al. Disease-modifying therapies in Alzheimer’s disease ⁎ ⁎ EDITOR’S NOTE: The Journal intended to include this article in the January 2008 supplement, “Leon Thal Symposium on Prevention of Dementia.” , 2008, Alzheimer's & Dementia.
[11] J. Cummings. Optimizing phase II of drug development for disease-modifying compounds , 2008, Alzheimer's & Dementia.
[12] Christopher Clark,et al. Disease-modifying therapies for Alzheimer disease , 2007, Neurology.
[13] J. Frédéric Bonnans,et al. Numerical Optimization: Theoretical and Practical Aspects (Universitext) , 2006 .
[14] P. Aisen. Commentary on “Challenges to demonstrating disease-modifying effects in Alzheimer’s disease clinical trials” , 2006, Alzheimer's & Dementia.
[15] Jeffrey L. Cummings,et al. Challenges to demonstrating disease-modifying effects in Alzheimer’s disease clinical trials , 2006, Alzheimer's & Dementia.
[16] Gina N. LaRossa,et al. [11C]PIB in a nondemented population , 2006, Neurology.
[17] J Philip Miller,et al. Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI , 2006, Neurology.
[18] C. Sampaio. Alzheimer disease: disease modifying trials; where are we? Where do we need to go? A reflective paper. , 2006, The journal of nutrition, health & aging.
[19] O. Rascol,et al. Disease modifying trials in Alzheimer disease: methodological and statistical issues. , 2006, The journal of nutrition, health & aging.
[20] Gina N. LaRossa,et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.
[21] Yvette I. Sheline,et al. Potential antecedent marker of Alzheimer disease , 2006 .
[22] Hendrik van den Bussche,et al. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials , 2005, BMJ : British Medical Journal.
[23] M. Citron,et al. Strategies for disease modification in Alzheimer's disease , 2004, Nature Reviews Neuroscience.
[24] D. Head,et al. Differential vulnerability of anterior white matter in nondemented aging with minimal acceleration in dementia of the Alzheimer type: evidence from diffusion tensor imaging. , 2004, Cerebral cortex.
[25] R. Mani. The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint , 2004, Statistics in medicine.
[26] F. Schmitt,et al. Designing a large prevention trial: statistical issues , 2004, Statistics in medicine.
[27] V. Gebski,et al. Inclusion of patients in clinical trial analysis: the intention‐to‐treat principle , 2003, The Medical journal of Australia.
[28] D. Jarjoura. Crossing controls to treatment in repeated-measures trials. , 2003, Controlled clinical trials.
[29] Jean Charles Gilbert,et al. Numerical Optimization: Theoretical and Practical Aspects , 2003 .
[30] G H Guyatt,et al. Intention-to-treat principle. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[31] L. Thal,et al. Clinical trial designs for demonstrating disease-course-altering effects in dementia. , 1998, Alzheimer disease and associated disorders.
[32] A Whitehead,et al. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration. , 1998, JAMA.
[33] R. Mohs,et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.
[34] P Leber,et al. Slowing the progression of Alzheimer disease: methodologic issues. , 1997, Alzheimer disease and associated disorders.
[35] R. Berger,et al. Uniformly More Powerful, One-sided Tests for Hypotheses about linear Inequalities , 1995 .
[36] P. Diggle. Analysis of Longitudinal Data , 1995 .
[37] E. M. Chi. Analysis of Cross‐Over Trials When Within‐Subject Errors Follow an AR(1) Process , 1992 .
[38] Roger L. Berger,et al. Uniformly More Powerful Tests for Hypotheses concerning Linear Inequalities and Normal Means , 1989 .
[39] Vijaya L. Melnick,et al. Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.
[40] K. Davis,et al. A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.
[41] Roger L. Berger,et al. Testing Hypotheses concerning Unions of Linear Subspaces , 1984 .
[42] J. Ware,et al. Random-effects models for longitudinal data. , 1982, Biometrics.
[43] B. Noble. Applied Linear Algebra , 1969 .